Novavax NVAX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 93.5%+23.2pp | 70.3%+5.2pp | 65.1%+10.6pp | 54.5%-45.5pp | |
| Operating margin | 40.3%+76.8pp | -36.5%+21.1pp | -57.6%-25.1pp | -32.5%+115pp | |
| Net margin | 39.2%+66.7pp | -27.5%+27.9pp | -55.4%-22.2pp | -33.2%+119pp | |
| EBITDA margin | 42.8%+72.1pp | -29.4%+24.0pp | -53.4%-22.3pp | -31.1%+115pp | |
| Returns | |||||
| Return on assets | 32.2%+43.3pp | -11.2%+15.7pp | -26.9%+0.3pp | -27.2%+56.6pp | |
| Efficiency | |||||
| Asset turnover | 0.8×+0.4× | 0.4×-0.1× | 0.5×-0.3× | 0.8×+0.3× | |
| Inventory turnover | 7.2×-0.8× | 8×-0.7× | 8.8×-30.9× | 39.6×— | |
| Liquidity | |||||
| Current ratio | 2.1×+1.1× | 1×+0.3× | 0.7×0.0× | 0.7×-0.2× | |
| Quick ratio | 2.1×+1.1× | 1×+0.3× | 0.7×0.0× | 0.7×-0.2× | |
| Cash ratio | 0.5×+0.1× | 0.5×+0.1× | 0.3×-0.2× | 0.5×-0.1× | |
| Leverage | |||||
| Debt-to-assets | 0.2×+0.2× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | 0.1×— | —— | —— | —— | |
| Interest coverage | 20.1×+32.5× | -12.4×+26.9× | -39.3×-6.9× | -32.4×+47.4× | |
| Per Share | |||||
| Book value per share | -$0.74+82.0% | -$4.10+42.4% | -$7.11+12.3% | -$8.11-71.6% | |
| Valuation | |||||
| Market capitalization | $1.46B+41.0% | $1.29B+126% | $570.19M-34.7% | $873.84M-91.9% | |
| Enterprise value | $1.53B+83.6% | $858.45M+390% | $175.37M+163% | -$279.22M-103% | |
| Price / earnings | 2.5×— | —— | —— | —— | |
| Price / sales | 2.5×+1.6× | 1.9×+1.3× | 0.6×+0.1× | 0.4×-9.0× | |
| EV / EBITDA | 2.4×— | —— | —— | —— | |
| EV / sales | 2.6×+1.9× | 1.3×+1.1× | 0.2×+0.3× | -0.1×-8.5× | |
| Earnings yield | -6%-52.1pp | -14.6%+81.0pp | -95.6%-20.3pp | -75.3%-59.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Novavax's profit margins?
- Novavax (NVAX) runs a 85.0% gross margin and a -13.1% operating margin, with a -14.7% net margin.
- Where do Novavax's ratios come from?
- Every ratio is computed from Novavax's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
